富马酸丙酚替诺福韦对HBV感染免疫耐受期孕妇母婴阻断效果及安全性评价

Evaluation of the Maternal And Infant Blockade Effect And Safety of Propofol Tenofovir Fumarate on HBV Infection in Immunotolerant Pregnant Women

目的研究富马酸丙酚替诺福韦对乙型肝炎病毒(HBV)感染免疫耐受期孕妇的母婴阻断效果及安全性。方法选取2021年1月至2023年1月在海南医学院第二附属医院诊治的28例HBV感染免疫耐受期孕妇,根据抗病毒方案分为富马酸替诺福韦二吡呋酯(TDF)组和富马酸丙酚替诺福韦(TAF)组。对比两组HBV DNA载量、肾小球滤过率(eGFR)、尿β2微球蛋白及不良反应发生率。结果两组治疗后HBV DNA较治疗前下降,P<0.05;两组治疗后eGFR与治疗前对比,P>0.05;治疗后TDF组尿β2微球蛋白较治疗前明显升高,且高于TAF组,P<0.05。两组不良反应发生率对比,P>0.05。两组新生儿HBV DNA、HBsAg和HBeAg检测结果均为阴性。结论对HBV感染免疫耐受期孕妇采用富马酸丙酚替诺福韦治疗的效果显著,可有效降低其HBV DNA载量,获得良好的母婴阻断效果,且对肾脏的安全性良好。

Objective:To Objective To study the blocking effect and safety of propofol fumarate on pregnant women infected with hepatitis B virus(HBV)in immune tolerance period.Methods:From January 2021 to January 2023,28 pregnant women with HBV infection in immune tolerance period were selected and divided into tenofovir dipivoxil fumarate(TDF)group and tenofovir dipivoxil fumarate(TAF)group according to the antiviral scheme.HBV DNA load,glomerular filtration rate(eGFR)、urinaryβ_(2)microglobulin and the incidence of adverse reactions were compared between the two groups.Results:HBV DNA in the two groups decreased after treatment compared with that before treatment,P<0.05;The eGFR of the two groups after treatment was compared with that before treatment,P>0.05;After treatment,urineβ2 microglobulin in TDF group was significantly higher than that before treatment,and it was higher than that in TAF group,P<0.05.The incidence of adverse reactions between the two groups was compared,P>0.05.The detection results of HBV DNA、HBsAg and HBeAg in newborns of both groups were negative.Conclusion:Propofovir fumarate is effective in the treatment of pregnant women with immune tolerance to HBV infection,which can effectively reduce their HBV DNA,obtain a good mother-to-child blocking effect,and is safe for pregnant women's kidneys.